The University of Southampton
University of Southampton Institutional Repository

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
Longitudinal quality of life (QOL) assessment is infrequently made in adjuvant therapy for colorectal cancer (CRC). This analysis aims to assess QOL and quality adjusted survival (QAS) in patients receiving adjuvant 5-FU for stage II and III CRC. We performed a multicentre study in which 801 patients were randomised to 6 months of bolus 5-FU/leucovorin (LV n = 404) or 12 weeks of protracted venous infusion (PVI) 5-FU (n = 397).
There were significant differences in the deterioration of QOL scores at week 2 with bolus 5-FU/LV compared to PVI 5-FU (P < 0.001), coinciding with toxicity peak during the first cycle. Following week 12, global QOL recovered to baseline when PVI 5-FU was stopped but this was delayed with bolus 5-FU/LV until completion at week 24. QOL scores significantly improved in both arms during follow-up (P < 0.001) and reached a plateau by year 1 without incremental improvement between years 2 and 5. There was a trend towards better QAS with PVI 5-FU. Twelve weeks of adjuvant PVI 5-FU was associated with significantly better QOL during treatment and faster time to recovery compared to 6 months of bolus 5-FU/LV.
colorectal cancer, adjuvant therapy, quality of life, 5-fu infusion
0959-8049
1551-1559
Chau, Ian
77e24001-6045-49ff-99c5-a49f708ba5da
Norman, Andrew R.
1bd65ddd-d4c6-468f-bc58-63ce0dd1b6e4
Cunningham, David
c40c8fe4-7eac-4b98-aaa5-b866da1e32ab
Iveson, Tim
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Hill, Mark
1dc95e98-aa1a-4b7c-a452-40d69477e414
Hickish, Tamas
585e80ad-7670-4fcd-9448-a454744ed486
Lofts, Fiona
df81b099-57b4-4e3e-a5b4-bd874d7f2d1a
Jodrell, Duncan
15c6b3de-6779-4a69-9309-17d418d8812a
Webb, Andrew
c62efeac-c6d4-4e45-8720-bc28e4c7fe04
Tait, Diana
670a46d4-5159-4318-8951-c0630049b6d4
Ross, Paul J.
beeaf105-3a23-47dc-a9e6-23cbebf3f4c5
Shellito, Pat
1c31f8dd-84e1-47da-94a1-f7a81a6af36e
Oates, Jacqueline R.
7c1c1755-21f0-4c82-8eed-565f74bdabef
Chau, Ian
77e24001-6045-49ff-99c5-a49f708ba5da
Norman, Andrew R.
1bd65ddd-d4c6-468f-bc58-63ce0dd1b6e4
Cunningham, David
c40c8fe4-7eac-4b98-aaa5-b866da1e32ab
Iveson, Tim
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Hill, Mark
1dc95e98-aa1a-4b7c-a452-40d69477e414
Hickish, Tamas
585e80ad-7670-4fcd-9448-a454744ed486
Lofts, Fiona
df81b099-57b4-4e3e-a5b4-bd874d7f2d1a
Jodrell, Duncan
15c6b3de-6779-4a69-9309-17d418d8812a
Webb, Andrew
c62efeac-c6d4-4e45-8720-bc28e4c7fe04
Tait, Diana
670a46d4-5159-4318-8951-c0630049b6d4
Ross, Paul J.
beeaf105-3a23-47dc-a9e6-23cbebf3f4c5
Shellito, Pat
1c31f8dd-84e1-47da-94a1-f7a81a6af36e
Oates, Jacqueline R.
7c1c1755-21f0-4c82-8eed-565f74bdabef

Chau, Ian, Norman, Andrew R., Cunningham, David, Iveson, Tim, Hill, Mark, Hickish, Tamas, Lofts, Fiona, Jodrell, Duncan, Webb, Andrew, Tait, Diana, Ross, Paul J., Shellito, Pat and Oates, Jacqueline R. (2005) Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 41 (11), 1551-1559. (doi:10.1016/j.ejca.2005.01.027).

Record type: Article

Abstract

Longitudinal quality of life (QOL) assessment is infrequently made in adjuvant therapy for colorectal cancer (CRC). This analysis aims to assess QOL and quality adjusted survival (QAS) in patients receiving adjuvant 5-FU for stage II and III CRC. We performed a multicentre study in which 801 patients were randomised to 6 months of bolus 5-FU/leucovorin (LV n = 404) or 12 weeks of protracted venous infusion (PVI) 5-FU (n = 397).
There were significant differences in the deterioration of QOL scores at week 2 with bolus 5-FU/LV compared to PVI 5-FU (P < 0.001), coinciding with toxicity peak during the first cycle. Following week 12, global QOL recovered to baseline when PVI 5-FU was stopped but this was delayed with bolus 5-FU/LV until completion at week 24. QOL scores significantly improved in both arms during follow-up (P < 0.001) and reached a plateau by year 1 without incremental improvement between years 2 and 5. There was a trend towards better QAS with PVI 5-FU. Twelve weeks of adjuvant PVI 5-FU was associated with significantly better QOL during treatment and faster time to recovery compared to 6 months of bolus 5-FU/LV.

This record has no associated files available for download.

More information

Published date: 2005
Keywords: colorectal cancer, adjuvant therapy, quality of life, 5-fu infusion

Identifiers

Local EPrints ID: 26242
URI: http://eprints.soton.ac.uk/id/eprint/26242
ISSN: 0959-8049
PURE UUID: 0a82bd21-362e-4da5-9382-24663b9f6395
ORCID for Tim Iveson: ORCID iD orcid.org/0000-0002-4681-2712

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 16 Mar 2024 02:58

Export record

Altmetrics

Contributors

Author: Ian Chau
Author: Andrew R. Norman
Author: David Cunningham
Author: Tim Iveson ORCID iD
Author: Mark Hill
Author: Tamas Hickish
Author: Fiona Lofts
Author: Duncan Jodrell
Author: Andrew Webb
Author: Diana Tait
Author: Paul J. Ross
Author: Pat Shellito
Author: Jacqueline R. Oates

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×